NCT01447303

Brief Summary

This study will compare changes in outcomes following viscosupplementation for knee osteoarthritis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2009

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

September 29, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 6, 2011

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2013

Completed
Last Updated

January 27, 2014

Status Verified

January 1, 2014

Enrollment Period

4.3 years

First QC Date

September 29, 2011

Last Update Submit

January 24, 2014

Conditions

Keywords

kneeosteoarthritishyaluronic acidviscosupplementation

Outcome Measures

Primary Outcomes (1)

  • Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    The (WOMAC) Index is a multidimensional, self-administered health status instrument for patients with osteoarthritis of the hip or knee. The index is a disease-specific, purpose built, high performance instrument for evaluative research in osteoarthritis clinical trials.

    Decsribes any change from baseline over a period of 12 months; the study subjects will complete the (WOMAC) Index at baseline, 1, 3, 6 and 12 months following the viscosupplementation of the knee.

Secondary Outcomes (6)

  • Visual Analog Scale (VAS) documentation of the level of knee pain. The (VAS) will describe the change in the level of knee pain from baseline following viscosupplementation of the knee.

    The study subjects will complete the (VAS) at baseline, 1, 3, 6 and 12 months following the viscosupplementation of the knee.

  • Medical Outcomes Short Form (SF-36); completed to describe any change in perceived Quality of Life (QOL) from baseline following viscosupplementation of the knee.

    The study subjects will complete the (SF-36) at baseline, 1, 3, 6 and 12 mos. following viscosupplementation of the knee.

  • Chair Rise Time; describes any change from baseline in time to rise from a chair following viscosupplementation of the knee

    The study subjects will complete the chair rise at baseline, 1, 3,6 and 12 mos. following viscosupplementation of the knee.

  • Stair Climb Time; describes any change in the time from baseline to walk up a flight of 12 steps following viscosupplementation of the knee

    The study subjects will complete the stair climb at baseline, 1, 3, 6 and 12 mos. following viscosupplementation of the knee.

  • Six Minute Walk Test; describes any change from baseline in leg pain following viscosupplementation of the knee.

    The study subjects will complete the six minute walk test at baseline, 1, 3, 6 and 12 mos. following viscosupplementation of the knee.

  • +1 more secondary outcomes

Study Arms (1)

Outcomes following viscosupplemantation

Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.

Other: Subject outcomes following viscosupplementation of the knee

Interventions

The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee

Outcomes following viscosupplemantation

Eligibility Criteria

Age21 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with symptomatic knee osteoarthritis.

You may qualify if:

  • years of age or older
  • osteoarthritis degeneration, degenerative joint disease or degeneration
  • fully cognizant of study procedures
  • willing to carefully participate in all study processes and assessments

You may not qualify if:

  • less that 21 years of age
  • allergic reactivity to hyaluronic acid
  • current knee infection, infection around injection site or any skin disease
  • pregnancy or lactation
  • non-ambulatory

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UF&Shands Orthopaedics and Sports Medicine Institute

Gainesville, Florida, 32607, United States

Location

MeSH Terms

Conditions

Osteoarthritis, KneeOsteoarthritis

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • Heather K Vincent, Ph.D.

    University of Florida Department of Orthopaedics and Rehabilitation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 29, 2011

First Posted

October 6, 2011

Study Start

August 1, 2009

Primary Completion

November 1, 2013

Study Completion

November 1, 2013

Last Updated

January 27, 2014

Record last verified: 2014-01

Locations